Purpose: This study compared the oncologic results of docetaxel chemotherapy (DOC) in castration-resistant prostate cancer (CRPC) according to continuous addition of androgen deprivation therapy (ADT) during chemotherapy.
INTRODUCTION
Prostate cancer (PCa) is the second most common cancer and the fifth leading cause of cancer-related death in males worldwide. 1 In Western countries, approximately 85% of newly diagnosed PCa cases remain localized to the prostate, whereas the remainder are advanced or metastatic. 2 In Korea, 21% of PCa patients present with distant metastases and 19% with locally advanced disease at diagnosis. 3 For the advanced PCa patients, androgen deprivation therapy (ADT) has been the main treatment option. However, despite an initial favorable response, the majority of patients experience predictable resistance to ADT after 3-5 years, which is defined as castration-resistant prostate cancer (CRPC). 4, 5 Accumulating evidence has indicated docetaxel chemotherapy (DOC) as a standard modality after progression to CRPC. 6, 7 Studies have highlighted the need to maintain ADT because PCa growth remains dependent on androgen receptor signaling. 8 However, it
is not fully understood whether continuous addition of ADT therapy during DOC actually provides survival benefits compared with conventional DOC without ADT.
Under the current guidelines, concurrent administration of luteinizing hormone-releasing hormone (LH-RH) agonist for CRPC patients under DOC is reimbursed by the Korean National Health Insurance System. However, as mentioned above, the benefits of concurrent administration of ADT in CRPC patients under cytotoxic chemotherapy are still debatable due to the absence of tangible results from related studies.
9,10
The aims of this study were therefore to examine the effect of concurrent use of ADT during DOC on clinical outcomes in Korean CRPC patients. The primary endpoints were biochemical progression-free survival (bPFS) and radiographic progression-free survival (rPFS) during DOC according to concurrent ADT use.
MATERIALS AND METHODS
Biochemical progression was defined as a ＞50% increase from the PSA nadir, with a minimum increase of 5 ng/mL. 12 The PSA nadir was defined as the lowest PSA level achieved during DOC. The time to biochemical progression was defined as the interval from the day of treatment initiation to biochemical progression. The time to radiographic progression was defined as the interval from the day of DOC initiation to the first occurrence of progression on imaging studies. Progression on bone scans was assessed according to the Prostate Cancer Working Group-2 criteria, 13 and soft tissue progression was evaluated with reference to the Response Evaluation Criteria in Solid Tumors version 1.1.
14 Differences in baseline characteristics were compared between groups using a chi-square test or Fisher exact test for categorical variables and the Mann-Whitney U-test for continuous variables. bPFS and rPFS were calculated and analyzed using the Kaplan-Meier method and the log-rank test. All of the tests were 2-sided, and p＜0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA).
RESULTS
Baseline patient characteristics are presented in Table 1 . Both groups were statistically similar in terms of age, PSA level, clinical stage and Gleason score, extent of metastasis at diagnosis, and biochemical/radiologic response to ADT. Table 2 shows clinical results of DOC for the 2 groups. DOC was administered for a median number of 6 cycles in both the DOC+continuous ADT group and DOC only group. The median time to DOC after initiation of primary ADT was Other reasons included patient refusal (n=6) and chemotherapy-related toxicities (n=24).
Kaplan-Meier analysis revealed a significant association between concurrent administration of ADT and prolonged bPFS (log-rank p=0.024) (Fig. 1A) . However, Kaplan-Meier analysis did not show a significant association between concurrent administration of ADT and prolonged rPFS (log-rank p=0.387) (Fig. 1B) .
DISCUSSION
DOC has been demonstrated to be efficacious and well tolerated in Western patients with advanced CRPC. 15, 16 This therapy was also shown to be efficacious in Korean patients with CRPC, with toxicities within acceptable limits and similar to those observed in Western patients. 17, 18 However, concurrent use of ADT for CRPC patients who receive DOC is a still a topic of debate. The rationale for continuing ADT when starting chemotherapy for CRPC is that cessation could lead to renewed release of testosterone and stimulation of the remaining androgen-sensitive elements of the tumor.
Regarding international guidelines, the European Association of Urology (EAU) guideline clearly states that, when CRPC develops,
ADT should be continued indefinitely. 19 In addition, the American Urological Association 20 and the National Comprehensive Cancer Network 21 also mention the need to maintain ADT when CRPC develops. However, the EAU guidelines are based on the data of a single study in which 85 men with CRPC refractory to orchiectomy received a chemotherapy regimen that is no longer used. 22 As a result, some investigators have doubts concerning this policy. Studies have shown that serum testosterone level remained under the castration level upon discontinuation of ADT within a certain period, and that second-line hormonal agents could replace the role of primary ADT even when disease progression was diagnosed after DOC. In fact, approximately 50% of men receiving ADT in the long term remain castrated for 2.5 years after stopping ADT, 23 although it should be noted that stopping ADT can reinduce hormone sensitivity. 24 These conflicting viewpoints are difficult to prove as there is a lack of well-designed prospective trials exploring this issue, and retrospective data are conflicting. 25, 26 In fact, there is no strong evidence that the combination of ADT with chemotherapy is beneficial for CRPC patients.
Recently, some pivotal trials of chemotherapy in PCa have stipulated that ADT should be continued when chemotherapy is initiated. To date, 2 studies have compared the clinical out-comes of DOC according to concurrent ADT use in Korean patients. Lee et al. 26 reported that patients treated with concurrent ADT during chemotherapy did not show significant clinical differences in progression-free survival and overall survival compared with patients who received DOC without ADT use. The proposed explanation was that serum testosterone level did not recover to the noncastrated level during the period of chemotherapy despite ADT withdrawal. However, a recent published article drew the opposite conclusion. Jang et al. 27 reported that the combined use of ADT with DOC improved radiologic progression-free survival in chemotherapy-naive patients with CRPC. They suggested that concurrent administration of ADT and DOC is superior to DOC alone and demonstrated that concurrent administration of ADT was the only significant predictor of radiologic progression-free survival using multivariable Cox regression analysis. However, they did not show a significant difference in overall survival according to concurrent use of ADT.
In the present study, our retrospective data analysis showed that biochemical recurrence-free survival was better in CRPC patients who received DOC with concurrent ADT than in those without ADT. Unfortunately, we could not prove a significant difference in radiologic-progression free survival; however, we believe that this is due to the different time interval of laboratory and imaging examinations. When CRPC patients received DOC, we usually performed laboratory examination including PSA every month, whereas radiologic examination was performed every 3 months according to Korean insurance guidelines. Moreover, most of enrolled patients in the early period of study underwent radiologic examination when the PSA level was checked in abruptly high. This could result in statistical bias. Furthermore, this was a retrospective study using patients who were diagnosed and treated more than 10 years ago, and we believe that if we used recently improved radiologic examinations including whole spine MRI, which is more sensitive than bone scan for detection of bone progression, we might detect radiologic progression earlier in patients who had treatment without concurrent ADT than in those with concurrent ADT.
In addition, we should discuss the role of concurrent ADT in second-line hormone therapy for CRPC patients. ADT plus chemotherapy versus ADT alone. 29 This is the one of the strongest reasons why concurrent ADT should be maintained in CRPC patients.
Our current study had several limitations inherent to a retrospective study including a limited number of patients. First, our data were retrospectively collected at multiple institutes, causing the results to be sensitive to selection bias. Also, concurrent
ADT use was performed in mainly one center. Second, many patients were excluded due to incomplete medical records.
Third, we could not show overall survival data because only a small proportion of patients died, and these patients were all from the early part of the study period. Almost all of the included patients received DOC recently. This study does not have enough power to detect the potential benefit of ADT. 
